Pfizer Stock News

Bourla said the two-dose vaccine has lost its protective power against infection and its ability to prevent hospitalization has also dropped.

Info comes via a Bloomberg report (may be gated) Pfizer Inc. is developing a hybrid vaccine that combines its original shot with a formulation that shields against the highly transmissible omicron variant While research continues, Pfizer will evaluate the new hybrid formulation a

Fourth Turning 2022: Bad-Moon Rising Authored by Jim Quinn via The Burning Platform blog, Try to unlearn the obsessive fear of death (and the anxious quest for death avoidance) that pervades linear thinking in nearly every modern society. The ancients knew that, without periodic decay and death, nature cannot complete its full round of biological and social change. Without plant death, weeds would strangle the forest. Without human death, memories would never die, and unbroken habits and customs would strangle civilization. Social institutions require no less. Just as floods replenish soil and fires rejuvenate forests, a Fourth Turning clears out societys exhausted elements and creates an opportunity. Strauss & Howe The Fourth Turning Institutions will be increasingly bossy, limiting personal freedoms, chastising bad manners, and cleansing the culture. Powerful new civic organizations will make judgments about which individual rights deserve respect and which do not. Criminal justice will become swift and rough, trampling on some innocents to protect an endangered and desperate society from those feared to be guilty.

100 "Fringe" Predictions For 2022 Submitted by QTR''s Fringe Finance Having already provided my semi-lengthy look at 22 stocks that I am watching heading into 2022 (you can view that far more serious post here ), I wanted to do something more fun, and less serious to open the new year. Heading into each new year, contained herein are 80 predictions of mine - void of all analysis and disclaiming any and all guarantees that I have any idea what I’m talking about . Absolutely none of these are to be considered life advice, investment advice or solicitations to buy or sell securities, sectors or industries mentioned. Please note that I have personal financial exposure to some elements in this list and that these are nothing more than wild-ass guesses, for fun, of what I think the coming year could bring. This list is for fun only - and is all opinion only. Photo: Diginomica It’ll be fun to look back at these predictions next year, when I make a similar list for 2023. And hey, at the very least, this list will serve as a handy reference guide as to how not worth it a paid subscription to my blog can be!

Stocks Analysis by Zacks Investment Research covering: Pfizer Inc. Read Zacks Investment Research''s latest article on Investing.com

The bloodbath continued for biotech stocks Monday despite massive deals for Pfizer and Bayer in gene-editing technology.

Pfizer Inc''s (NYSE: PFE ) CEO Albert Bourla said that the omicron-targeted vaccine of COVID-19 will be ready in March , and the Company has already begun manufacturing the doses. "This vaccine will be ready in March," Bourla told CNBC''s " Squawk Box ." "We [are] already starting manufacturing some of these quantities at risk." Bourla said the vaccine would also target the other variants that are circulating. He said it is still Full story available on Benzinga.com

Pfizer''s CEO Albert Bourla gave a timeline for when an Omicron vaccine, if needed, would be ready.

The CEO of Pfizer, Albert Bourla, has said that a vaccine for the highly transmissible Omicron variant of Covid-19 will be ready in March and that the pharmaceutical company has begun manufacturing the doses.

Pfizer CEO Albert Bourla said Monday that a trio of deals increasing the firm''s investment in mRNA development will leverage this "powerful technology" to find "solutions for unmet…

Pfizer CEO Albert Bourla said a vaccine that specifically targets the omicron variant of Covid will be ready in March, and the company''s already begun manufacturing the doses.

Biotech stocks came under selling pressure along with the broader market, as rate hike fears seized Wall Street. The news flow, however, was scanty. Last week, the Food and Drug Administration expanded the emergency use authorization it accorded for the Pfizer, Inc. (NYSE: PFE )- BioNTech SE (NASDAQ: BNTX ) vaccine. The expanded approval allows the use of a single booster dose in individuals 12 through 15 years of age, a third primary series dose for certain immunocompromised children 5 through 11 years of age, and the shortening of time between completion of primary vaccination and a booster dose to at least five months. Clinical readouts resulted in contrasting stock moves. Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT ) ended the week up about 80% after its lead candidate LB-100 was found to increase the responsiveness of diverse cancers to immunotherapy. On the other hand, Aligos Therapeutics, Inc. (NASDAQ: Full story available on Benzinga.com

Stocks Analysis by Zacks Investment Research covering: Eli Lilly and Company, Pfizer Inc, Incyte Corporation, AbbVie Inc. Read Zacks Investment Research''s latest article on Investing.com

(RTTNews) - Pfizer (PFE) said that it has entered into an agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics. The agreement expands Pfizer''s access to lipid nanoparticle (LNP) formulation technology, offering a strong strategic fit with Pfizer''s mRNA strategy. Acuitas''